Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

840P - Preliminary phase I/II study results of orelabrutinib combined with MIL62 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Date

16 Sep 2021

Session

ePoster Display

Presenters

Yuan-Kai Shi

Citation

Annals of Oncology (2021) 32 (suppl_5): S773-S785. 10.1016/annonc/annonc676

Authors

Y. Shi1, Y. Qin1, W. Zhang2, X. Wang3, H. Liu4, A. Zang5, L. Yang6, D. Lin7, F. Li7, H. Zhu8, R. Zhao8

Author affiliations

  • 1 Medical Oncology Dept., Chinese Academy of Medical Sciences - National Cancer Center, Cancer Hospital, 100021 - Beijing/CN
  • 2 Lymphoma Dept., Beijing Shijitan Hosptials, 100038 - Beijing/CN
  • 3 Phase I Clinical Trial Center, Beijing Shijitan Hosptials, 100038 - Beijing/CN
  • 4 Hematology, Beijing Hospital, 100730 - Beijing/CN
  • 5 Oncology Department, Affiliated Hospital of Hebei University, 71000 - Baoding/CN
  • 6 Hematology, The first Affiliated Hospital of Bengbu Medical College, 233017 - Bengbu/CN
  • 7 Medical Research, Beijing Mabworks Biotech Co.Ltd, 100176 - Beijing/CN
  • 8 Medical Research, Beijing InnoCare Pharma Tech Co., Ltd, 102206. - Beijing/CN
More

Abstract 840P

Background

MIL62 is a glycoengineered anti-CD20 antibody with a nearly completely afucosylated N-glycans in Fc region that demonstrated superior activity in comparison with rituximab and obinutuzumab in vitro and in vivo, respectively. Orelabrutinib (ICP-022) is a novel and highly selective irreversible Bruton’s tyrosine kinase (BTK) inhibitor that does not affect IL2-associated tyrosine kinase (ITK) or antibody-dependent cellular cytotoxicity, making it an attractive candidate for combined therapy with anti-CD20 antibodies.

Methods

This was a phase I/IIa dose escalation and dose expansion study (NCT 04304040), which investigated orelabrutinib in combination with MIL62 for the treatment of patients with relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (NHL). The dose escalation was conducted with a standard 3 + 3 dose scheme in different dose combinations of orelabrutinib 100 mg or 150 mg oral daily combined with MIL62 injection 800 mg or 1000 mg, respectively.

Results

A total of 14 patients with r/r CD20-positive B-cell NHL(10 diffuse large B-cell lymphoma [DLBCL], 2 mantle cell lymphoma, 1 follicular lymphoma, 1 marginal zone lymphoma) were enrolled across 5 centers in China. Median age was 62.5 (range, 38‒77) years and 50% of patients were male. Overall, 78.6% of patients had received ≥2 lines systemic therapies. No dose-limiting toxicity (DLT) or unexpected adverse events were observed. The treatment emergent adverse events (TEAE) of any grade were thrombocytopenia (5/14, 35.7%), infusion-related reaction (3/14, 21.4%) and hyperuricemia (3/14, 21.4%). Only 2 patients were observed ≥3 grade TEAE, with one leukopenia/neutropenia deeming treatment related. Ten patients were evaluable for efficacy as of data cut-off on Apr. 21, 2021. Objective response rate (ORR) was 70%, with 3 complete response (CR) and 4 partial response (PR). ORR was 71.4% for DLBCL, including 3 CR, 2 PR. All patients except 2 remain on therapy and the longest duration of treatment is 8.5 months at cut-off date.

Conclusions

Orelabrutinib and MIL62 combination therapy was generally well tolerated without unexpected toxicities and demonstrated encouraging clinical activity in patients with relapsed/refractory B-cell NHL.

Clinical trial identification

NCT04304040.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Beijing Innocare Pharma Tech Co. Ltd.; Beijing Mabworks Biotech Co. Ltd.

Disclosure

D. Lin: Financial Interests, Personal, Full or part-time Employment: Beijing Mabworks Biotech Co. Ltd. F. Li: Financial Interests, Invited Speaker: Beijing Mabworks Biotech Co. Ltd. H. Zhu, R. Zhao: Financial Interests, Personal, Full or part-time Employment: Beijing Innocare Pharma Tech Co. Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.